Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Weill Cornell Medicine teams receive funding from Starr Cancer Consortium

Weill Cornell Medicine teams receive funding from Starr Cancer Consortium

Research uncovers intrinsic factors influencing CAR-T cell success

Research uncovers intrinsic factors influencing CAR-T cell success

Researchers uncover the link between EVs and tissue damage

Researchers uncover the link between EVs and tissue damage

Exposure to polycyclic aromatic hydrocarbons may increase cancer risk

Exposure to polycyclic aromatic hydrocarbons may increase cancer risk

Study identifies key blood stem cells in immune system aging

Study identifies key blood stem cells in immune system aging

Researchers identify mechanism of immune suppression in ovarian cancer

Researchers identify mechanism of immune suppression in ovarian cancer

myeloMATCH program opens enrollment for acute myeloid leukemia and MDS

myeloMATCH program opens enrollment for acute myeloid leukemia and MDS

NIH launches precision medicine trial to test new treatments for myeloid cancers

NIH launches precision medicine trial to test new treatments for myeloid cancers

Researchers discover how ovarian tumors cripple immune cells

Researchers discover how ovarian tumors cripple immune cells

Groundbreaking findings on TET2 pathway open doors for targeted blood cancer treatments

Groundbreaking findings on TET2 pathway open doors for targeted blood cancer treatments

U.S. cancer detection severely disrupted during first year of COVID-19, shows incomplete recovery in second year

U.S. cancer detection severely disrupted during first year of COVID-19, shows incomplete recovery in second year

UCLA and Parker Institute renew alliance to advance cancer immunotherapy

UCLA and Parker Institute renew alliance to advance cancer immunotherapy

Harris backs slashing medical debt. Trump’s ‘concepts’ worry advocates.

Harris backs slashing medical debt. Trump’s ‘concepts’ worry advocates.

Case Western Reserve University receives grant to investigate AML treatment for veterans

Case Western Reserve University receives grant to investigate AML treatment for veterans

Evaluating allogeneic transplant for TP53 mutated acute myeloid leukemia

Evaluating allogeneic transplant for TP53 mutated acute myeloid leukemia

Researchers develop innovative mouse model for studying cancer immunotherapy

Researchers develop innovative mouse model for studying cancer immunotherapy

CRISPR-based rapid molecular diagnostic developed for two forms of leukemia

CRISPR-based rapid molecular diagnostic developed for two forms of leukemia

Gene therapy offers hope for children with cerebral adrenoleukodystrophy

Gene therapy offers hope for children with cerebral adrenoleukodystrophy

Concerns rise over increased industry sponsorship in cancer clinical trials

Concerns rise over increased industry sponsorship in cancer clinical trials

Epigenetic testing opens new doors for multiple myeloma treatment

Epigenetic testing opens new doors for multiple myeloma treatment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.